Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage

Area of Science:

• Neuroscience
• Cellular Biology
• Pathology

Background:

• Prolonged seizures (status epilepticus; SE) lead to cognitive impairments and dendritic injury.
• The mammalian target of rapamycin complex 1 (mTORC1) pathway is hyperactivated after SE and influences learning, memory, and neuronal structure.
• Mechanisms linking SE-induced mTORC1 hyperactivity to cognitive deficits and dendritic pathology are not fully understood.

Purpose of the Study:

• To investigate if mTORC1 hyperactivation mediates cognitive deficits and dendritic pathology following SE.
• To determine the therapeutic potential of inhibiting mTORC1 in mitigating SE-induced impairments.

Main Methods:

• Pilocarpine-induced SE in rats was used to model status epilepticus.
• Rapamycin, an mTORC1 inhibitor, was administered to SE rats.
• Spatial learning and memory were assessed using the Morris water maze and novel object recognition tests.
• Molecular analyses examined mTORC1 signaling, microgliosis, dendritic markers (Map2), ion channels, dendritic branching, and spine density in the hippocampus.

Main Results:

• Rapamycin treatment significantly improved spatial learning and memory in SE rats compared to controls.
• SE-induced mTORC1 hyperactivation was observed in neurons and microglia.
• Rapamycin reduced mTOR activation, attenuated microgliosis in the CA1 area, and reversed SE-induced decreases in dendritic Map2 and ion channel levels.
• Rapamycin treatment also improved dendritic branching and spine density in the CA1 area.

Conclusions:

• mTORC1 hyperactivity is a key contributor to early hippocampal-dependent spatial learning and memory deficits following SE.
• Inhibition of mTORC1 with rapamycin can ameliorate cognitive impairments and dendritic dysregulation associated with SE.
• Targeting the mTORC1 pathway may offer a therapeutic strategy for managing cognitive sequelae of status epilepticus.